Histologix Ltd - One of the UK’s Leading Independent, GLP/GCP Accredited Laboratories for specialised histology, biomarker and immune-oncology Quantitative IHC and ISH Tissue Expression Services. Formed in 2005, Histologix Ltd is a GLP & GCP accredited CRO, licenced by the Human Tissue Authority, that provides the Pharmaceutical and Biotechnology industry with specialist Histopathology services to assist our client’s drug development programmes from Discovery and regulatory preclinical safety testing through to clinical trials. Services include; Human tissue sourcing, Histology, Medical and Veterinary Pathologist review, Immunohistochemistry and in situ hybridisation, Tissue Cross-Reactivity of Therapeutic Antibodies, Over-expressing cell line and xenograft studies - In-vitro efficacy studies, Target Development and Distribution, Angiogenesis, Cell Proliferation/Apoptosis, Tumour and Stromal immune cell phenotyping, Biosimilar efficacy, Validated and optimised IHC immuno-oncology biomarker assays together with next generation quantitative image analysis clinical trial support, IHC Multiplexing using fluorescent and chromogenic systems, Digital Pathology, Patient recruitment/stratification, Through Collaboration We offer validated in vitro and in vivo models in: • Immuno-oncology • Autoimmune disease • Inflammation and allergy • Anti-microbials, anti-virals and vaccinology As part of our Immuno-Oncology service Histologix offers immune cell biomarker assays, checkpoint inhibitor assays and a range of dual and multiplexed staining assays that will provide functional readouts and additional mechanistic information and understanding of the tumour immune microenvironment, which in turn delivers a valuable immunological insight into tumour immune processes. Image analysis algorithms are critical within this process to consistently localise staining and to reproducibly measure the proximity and spatial relationships between immune cells within the tumour microenvironment and surrounding stroma. The HistologiX science-led Immuno-oncology team consists of Marie Cumberbatch (Director, Immune Insight Ltd and former Molecular Pathology Team Leader in Translational Science at AstraZeneca specialising in immuno-oncology), Professor Adam Hargreaves (Director, PathCelerate Ltd, British (FRCPath), American (DiplACVP) board-certified veterinary and toxicologic histopathologist), and Professor Chris Womack (Chairman of HistologiX Ltd and former Head of Oncology Molecular Pathology group, AstraZeneca). Histologix has clients throughout UK, EU, Scandanavia, Switzerland, Russia, Canada and the USA.